NF-56-EJ40
![]() | |
Identifiers | |
---|---|
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
ChemSpider | |
ChEMBL | |
Chemical and physical data | |
Formula | C27H29N3O3 |
Molar mass | 443.547 g·mol−1 |
3D model (JSmol) | |
| |
|
NF-56-EJ40 is an experimental drug which acts as a potent and selective antagonist for the succinate receptor SUCNR1 (GPR91). It has antiinflammatory effects and has been used to investigate the role of succinate in the development of conditions such as atherosclerosis and ulcerative colitis.[1][2][3][4]
References
- ^ Haffke M, Fehlmann D, Rummel G, Boivineau J, Duckely M, Gommermann N, et al. (October 2019). "Structural basis of species-selective antagonist binding to the succinate receptor". Nature. 574 (7779): 581–585. Bibcode:2019Natur.574..581H. doi:10.1038/s41586-019-1663-8. PMID 31645725.
- ^ Xu J, Zheng Y, Zhao Y, Zhang Y, Li H, Zhang A, et al. (2022). "Succinate/IL-1β Signaling Axis Promotes the Inflammatory Progression of Endothelial and Exacerbates Atherosclerosis". Frontiers in Immunology. 13: 817572. doi:10.3389/fimmu.2022.817572. PMC 8901997. PMID 35273600.
- ^ Shenol A, Lückmann M, Trauelsen M, Lambrughi M, Tiberti M, Papaleo E, et al. (March 2024). "Molecular dynamics-based identification of binding pathways and two distinct high-affinity sites for succinate in succinate receptor 1/GPR91". Molecular Cell. 84 (5): 955–966.e4. doi:10.1016/j.molcel.2024.01.011. PMID 38325379.
- ^ Huo L, Chen Q, Jia S, Zhang Y, Wang L, Li X, et al. (August 2025). "Gut microbiome promotes succinate-induced ulcerative colitis by enhancing glycolysis through SUCNR1/NF-κB signaling pathway". American Journal of Physiology. Cell Physiology. 329 (2): C440 – C454. doi:10.1152/ajpcell.00411.2025. PMID 40549551.